Inhibrx Biosciences Q2 EPS $125.48, Sales $100.00K Up From $30.00K YoY
Portfolio Pulse from Benzinga Newsdesk
Inhibrx Biosciences (NASDAQ:INBX) reported a significant improvement in its Q2 earnings, with EPS of $125.48, a 3011.37% increase from the previous year's loss of $(4.31) per share. Sales also rose by 233.33% to $100.00K from $30.00K YoY.
August 14, 2024 | 7:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inhibrx Biosciences reported a remarkable Q2 EPS of $125.48, a 3011.37% increase from last year's loss of $(4.31) per share. Sales also increased by 233.33% to $100.00K. This strong financial performance is likely to positively impact the stock price in the short term.
The significant increase in EPS and sales indicates strong financial performance, which is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100